Paraneoplastic neurological syndrome in the course of breast cancer Case report

Main Article Content

Anna Ciszewska
Łukasz Głogowski
Andrzej Witkoś
Zofia Rusinowska
Ewa Nowakowska-Zajdel

Abstract

Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases. They have a typically aggressive course, leading to profound and essentially irreversible disability. The pathogenic cause behind PNS is damage of the nervous system structures as a consequence of the body’s immunological reaction induced by cancer. Onconeural antibodies generated as part of the reaction target the tumour tissues, but also the regular nervous tissue recognized as antigens. Presence of onconeural antibodies reveals a 50–60% sensitivity and 100% specificity in diagnosing PNS. Imaging and laboratory tests have a limited impact on diagnosis. What is crucial is the analysis of clinical systems following Graus’s criteria (elaborated in 2004). In the case presented here, the patient underwent treatment in many neurological departments due to the symptoms of progressive damage of the nervous system. She was eventually diagnosed with the stiff person syndrome related to breast cancer. In spite of the treatment, including an efficacious oncological therapy, the severe neurological deficit resulted in serious motor disability.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Ciszewska A, Głogowski Łukasz, Witkoś A, Rusinowska Z, Nowakowska-Zajdel E. Paraneoplastic neurological syndrome in the course of breast cancer. OncoReview [Internet]. 2015Mar.30 [cited 2024Nov.23];5(2(18):76-0. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/392
Section
Articles

References

1. Chabner BA, Lynch TJ, Longo DL. Harrison Onkologia 2009: 421-427.
2. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies. Neurology 2008; 71(24): 1955-1958.
3. Titulaer MJ, Soffietti R, Dalmau J et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011; 18(1): 19-e3.
4. Didelot A, Honnorat J. Neurologiczne zespoły paranowotworowe [Paraneoplastic Neurological Syndromes]. Onkologia po Dyplomie 2010; 7(1): 38-46.
5. Badanie w kierunku obecności przeciwciał przeciwneuronalnych w surowicy krwi oraz ich specyfikacja [Tests for onconeural antibodies in blood serum and their specification]. Online: www.ipin.edu.pl/Kiz/neurologia2/76,ktm.
6. Rogoziewicz M, Michalak S. Neurologiczne zespoły paraneoplastyczne – etiopatogeneza i diagnostyka [Paraneoplastic neurological syndromes – aetiopathogenesis and diagnostics]. Onkologia Polska 2011; 14(1): 26-29.
7. Michalak S, Kozubski W. Neurologiczne zespoły paranowotworowe [Paraneoplastic Neurological Syndromes. Polski Przegląd Neurologiczny 2008; 4(1): 26-31.
8. Krzakowski M. Zespoły paranowotworowe [Paraneoplastic Syndromes]. Polska Medycyna Paliatywna 2002; (2): 57-66.
9. Gozzard P, Maddison P. Jakie przeciwciało i jaki nowotwór w którym zespole paranowotworowym? [Which antibody and which cancer in which paraneoplastic syndromes?]. Medycyna Praktyczna 2010/06: 260-270.
10. Pankaj AA, Nasli RI. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff-person syndrome associated with carcinoma the breast Neurology India Publication of the Neurological Society of India 2010, 58(3): 449-451.